HUMACYTE INC (HUMA) Stock Fundamental Analysis

NASDAQ:HUMA • US44486Q1031

1.01 USD
0 (0%)
At close: Feb 12, 2026
1.0185 USD
+0.01 (+0.84%)
After Hours: 2/12/2026, 8:00:02 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

1

Overall HUMA gets a fundamental rating of 1 out of 10. We evaluated HUMA against 523 industry peers in the Biotechnology industry. HUMA may be in some trouble as it scores bad on both profitability and health. HUMA is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • HUMA had negative earnings in the past year.
  • HUMA had a negative operating cash flow in the past year.
  • In the past 5 years HUMA always reported negative net income.
  • In the past 5 years HUMA always reported negative operating cash flow.
HUMA Yearly Net Income VS EBIT VS OCF VS FCFHUMA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -50M -100M

1.2 Ratios

  • The Return On Assets of HUMA (-40.46%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -40.46%
ROE N/A
ROIC N/A
ROA(3y)-66.77%
ROA(5y)-54.38%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
HUMA Yearly ROA, ROE, ROICHUMA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 200 -200 -400 -600 -800

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for HUMA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
HUMA Yearly Profit, Operating, Gross MarginsHUMA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

1

2. Health

2.1 Basic Checks

  • The number of shares outstanding for HUMA has been increased compared to 1 year ago.
  • Compared to 5 years ago, HUMA has more shares outstanding
  • The debt/assets ratio for HUMA has been reduced compared to a year ago.
HUMA Yearly Shares OutstandingHUMA Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
HUMA Yearly Total Debt VS Total AssetsHUMA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

  • Based on the Altman-Z score of -13.14, we must say that HUMA is in the distress zone and has some risk of bankruptcy.
  • HUMA's Altman-Z score of -13.14 is on the low side compared to the rest of the industry. HUMA is outperformed by 76.86% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -13.14
ROIC/WACCN/A
WACCN/A
HUMA Yearly LT Debt VS Equity VS FCFHUMA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

  • HUMA has a Current Ratio of 1.62. This is a normal value and indicates that HUMA is financially healthy and should not expect problems in meeting its short term obligations.
  • With a Current ratio value of 1.62, HUMA is not doing good in the industry: 79.16% of the companies in the same industry are doing better.
  • A Quick Ratio of 0.90 indicates that HUMA may have some problems paying its short term obligations.
  • Looking at the Quick ratio, with a value of 0.90, HUMA is doing worse than 85.66% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.62
Quick Ratio 0.9
HUMA Yearly Current Assets VS Current LiabilitesHUMA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • HUMA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 82.84%, which is quite impressive.
EPS 1Y (TTM)82.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%66.67%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, HUMA will show a very strong growth in Earnings Per Share. The EPS will grow by 38.13% on average per year.
  • The Revenue is expected to grow by 384.64% on average over the next years. This is a very strong growth
EPS Next Y75.23%
EPS Next 2Y28%
EPS Next 3Y20.11%
EPS Next 5Y38.13%
Revenue Next Year1218.54%
Revenue Next 2Y946.79%
Revenue Next 3Y653.56%
Revenue Next 5Y384.64%

3.3 Evolution

HUMA Yearly Revenue VS EstimatesHUMA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 1B 2B 3B
HUMA Yearly EPS VS EstimatesHUMA Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 5 10

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • HUMA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for HUMA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
HUMA Price Earnings VS Forward Price EarningsHUMA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
HUMA Per share dataHUMA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.1 -0.2 -0.3 -0.4 -0.5

4.3 Compensation for Growth

  • A more expensive valuation may be justified as HUMA's earnings are expected to grow with 20.11% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y28%
EPS Next 3Y20.11%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for HUMA!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

HUMACYTE INC

NASDAQ:HUMA (2/12/2026, 8:00:02 PM)

After market: 1.0185 +0.01 (+0.84%)

1.01

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12
Earnings (Next)03-26
Inst Owners24.12%
Inst Owner Change3.13%
Ins Owners5.81%
Ins Owner Change2.24%
Market Cap189.14M
Revenue(TTM)1.57M
Net Income(TTM)-37.03M
Analysts81.54
Price Target7.87 (679.21%)
Short Float %23.92%
Short Ratio7.84
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-6.83%
Min EPS beat(2)-45.54%
Max EPS beat(2)31.89%
EPS beat(4)3
Avg EPS beat(4)67.02%
Min EPS beat(4)-45.54%
Max EPS beat(4)244.48%
EPS beat(8)4
Avg EPS beat(8)14.72%
EPS beat(12)7
Avg EPS beat(12)11.48%
EPS beat(16)10
Avg EPS beat(16)42.93%
Revenue beat(2)0
Avg Revenue beat(2)-45.27%
Min Revenue beat(2)-70.58%
Max Revenue beat(2)-19.96%
Revenue beat(4)0
Avg Revenue beat(4)-55.97%
Min Revenue beat(4)-100%
Max Revenue beat(4)-19.96%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-1.82%
PT rev (3m)-8.47%
EPS NQ rev (1m)0%
EPS NQ rev (3m)10.23%
EPS NY rev (1m)-26.45%
EPS NY rev (3m)9.56%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-36.72%
Revenue NY rev (1m)-4.54%
Revenue NY rev (3m)-22.3%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 120.4
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.23
EYN/A
EPS(NY)-0.46
Fwd EYN/A
FCF(TTM)-0.57
FCFYN/A
OCF(TTM)-0.56
OCFYN/A
SpS0.01
BVpS-0.03
TBVpS-0.03
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -40.46%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-66.77%
ROA(5y)-54.38%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 12.31%
Cap/Sales 57.73%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.62
Quick Ratio 0.9
Altman-Z -13.14
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)21.4%
Cap/Depr(5y)14.14%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)82.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%66.67%
EPS Next Y75.23%
EPS Next 2Y28%
EPS Next 3Y20.11%
EPS Next 5Y38.13%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year1218.54%
Revenue Next 2Y946.79%
Revenue Next 3Y653.56%
Revenue Next 5Y384.64%
EBIT growth 1Y6.33%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year48.92%
EBIT Next 3Y28.21%
EBIT Next 5Y25.39%
FCF growth 1Y-39.37%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-43.48%
OCF growth 3YN/A
OCF growth 5YN/A

HUMACYTE INC / HUMA FAQ

What is the fundamental rating for HUMA stock?

ChartMill assigns a fundamental rating of 1 / 10 to HUMA.


What is the valuation status for HUMA stock?

ChartMill assigns a valuation rating of 1 / 10 to HUMACYTE INC (HUMA). This can be considered as Overvalued.


Can you provide the profitability details for HUMACYTE INC?

HUMACYTE INC (HUMA) has a profitability rating of 0 / 10.


How financially healthy is HUMACYTE INC?

The financial health rating of HUMACYTE INC (HUMA) is 1 / 10.